---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-008507"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:26:56.743340+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte Q1 net loss $39M, cash $352M; VAX-24 topline results due end-2022

## Summary
- Q1 net loss $39.0M vs $21.2M YoY; R&D $31.7M, G&A $7.5M.
- Cash, cash equivalents and investments $352.3M at March 31, 2022, including $107.6M net from public offering.
- VAX-24 Phase 1/2 study dosing in both phases; topline safety, tolerability, immunogenicity results expected by year-end 2022.
- Separate VAX-24 Phase 2 study in adults 65+ expected to start mid-2022; topline results expected H1 2023.
- Appointed Mikhail Eydelman as SVP, General Counsel & Corporate Secretary in April 2022.

## SEC filing metadata
- accession: 0000950170-22-008507
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000095017022008507/0000950170-22-008507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000095017022008507/pcvx-20220509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-008507
- JSON: https://secwatch.observer/filing/0000950170-22-008507.json
- Plain text: https://secwatch.observer/filing/0000950170-22-008507.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.